Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

pembrolizumab 299Carboplatin 229Cisplatin 159Gemcitabine 152Paclitaxel 151Pemetrexed 121Bevacizumab 121Docetaxel 106Oxaliplatin 82durvalumab 81Nivolumab 81Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 77130-nm albumin-bound paclitaxel 73Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 56fludarabine 51Lenalidomide 50venetoclax 46Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cytochrome P-450 CYP1A2 × 90 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡